FCCC LOGO Faculty Publications
Craig AD , Garcia E , Peters PN , Chen LM , Chapman JS
Primary treatment of advanced ovarian cancer: how does the 'real world' practice?
Future Oncol. 2021 Aug 26
Back to previous list
Abstract
Aims: This study evaluated primary treatment modalities in advanced ovarian cancer according to sociodemographic characteristics and characterized chemotherapy regimens used. Methods: This was a retrospective study of newly diagnosed advanced ovarian, tubal or peritoneal cancer patients at two hospitals from 2011 to 2016. Results: Of 175 women, 41% received neoadjuvant chemotherapy and 59% received primary cytoreductive surgery. Within the neoadjuvant chemotherapy group, 23% did not have a surgical consultation prior to initiating treatment. Women receiving neoadjuvant chemotherapy lived closer to an academic center and more frequently received carboplatin/paclitaxel every 3 weeks. Cytoreductive surgery patients more frequently received intraperitoneal chemotherapy. Conclusion: The authors identified disparities in age, insurance, distance from treatment center and chemotherapy choice in the primary treatment for ovarian cancer. Lay abstract Aims: This study evaluated surgery versus chemotherapy in stage III or IV ovarian cancer and whether differences exist between different groups of patients. Methods: This study looked at newly diagnosed stage III/IV ovarian, tubal or peritoneal cancer patients at two hospitals from 2011 to 2016. Results: Of 175 women, 41% received neoadjuvant chemotherapy and 59% received primary cytoreductive surgery. Within the neoadjuvant chemotherapy group, 23% did not see a gynecologic oncologist prior to initiating treatment. Women receiving neoadjuvant chemotherapy lived closer to an academic center and more frequently received carboplatin/paclitaxel every 3 weeks. Cytoreductive surgery patients more frequently received intraperitoneal chemotherapy. Conclusion: The authors identified differences in age, insurance, distance from treatment center and chemotherapy choice in the treatment for ovarian cancer. eng
Notes
1744-8301 Craig, Amaranta D Orcid: 0000-0002-0233-9089 Garcia, Eduardo Orcid: 0000-0002-8334-1382 Peters, Pamela N Orcid: 0000-0002-6259-3054 Chen, Lee-May Orcid: 0000-0003-3370-0161 Chapman, Jocelyn S Orcid: 0000-0002-4260-3016 Journal Article England Future Oncol. 2021 Aug 26. doi: 10.2217/fon-2021-0086.